v3.26.1
Segment Reporting (Tables)
 6 Months Ended
Jun. 30, 2026
Segment Reporting [Abstract]  
Summary of Reportable Revenues by Geographic Regions The following table summarizes reportable revenue by geographic regions (in thousands):
Three Months Ended June 30,Six Months Ended June 30,
2026202520262025
Testing services revenue
United States$99,548 $61,670 $190,577 $123,108 
Rest of World379 363 748 846 
$99,927 $62,033 $191,325 $123,954 
Product revenue
United States$7,885 $7,193 $14,579 $13,700 
Rest of World4,906 4,640 8,558 8,943 
$12,791 $11,833 $23,137 $22,643 
Patient and digital solutions revenue
United States$19,193 $12,778 $35,116 $24,698 
Rest of World37 35 70 69 
$19,230 $12,813 $35,186 $24,767 
Total revenue
Total United States$126,626 $81,641 $240,272 $161,506 
Total Rest of World5,322 5,038 9,376 9,858 

$131,948 $86,679 $249,648 $171,364 
Summary of Long-Lived Assets Consisting of Property and Equipment, Net by Geographic Regions
The following table summarizes long-lived assets, consisting of property and equipment, net, by geographic regions (in thousands):
June 30, 2026December 31, 2025
Long-lived assets:
United States$26,838 $32,635 
Rest of World— 336 
Total$26,838 $32,971 
Summary of Reconciliation of Revenue to Net Income (Loss)
The following table summarizes the reconciliation to net income (loss) (in thousands):
Three Months Ended June 30,Six Months Ended June 30,
2026202520262025
Revenue:
Testing services revenue
$99,927 $62,033 $191,325 $123,954 
Product revenue
12,791 11,833 23,137 22,643 
Patient and digital solutions revenue
19,230 12,813 35,186 24,767 
Total revenue
131,948 86,679 249,648 171,364 
Less:
Cost of testing services1
15,516 14,731 32,037 29,134 
Cost of product1
4,327 4,431 8,560 9,374 
Cost of patient and digital solutions1
14,447 7,929 25,859 15,273 
Personnel cost
49,033 29,330 91,221 60,073 
Professional and legal fees
5,861 12,348 13,773 22,540 
Research materials and clinical trials expense
4,088 4,057 7,919 7,231 
Depreciation and amortization expense
2,057 2,951 5,176 5,901 
Stock-based compensation expense
10,615 9,424 20,382 18,355 
Litigation settlement expense
— 350 600 5,710 
Business development and portfolio optimization expense2
11,078 — 14,435 — 
Transformational initiative costs— 1,871 — 1,871 
Gain on sale of lab products business(112,966)— (112,966)— 
Other segment items3
18,991 10,189 32,851 19,970 
Interest income, net
(1,735)(2,364)(3,644)(5,147)
Segment and condensed consolidated net income (loss)
$110,636 $(8,568)$113,445 $(18,921)
1 Cost of testing services, cost of product and cost of patient and digital solutions include depreciation expense.
2 Business development and portfolio optimization expense primarily includes legal, consulting, financial advisory, due diligence, and other transaction-related costs incurred in connection with business development activities, including the sale of lab products business and the acquisition of Naveris, Inc.
3 Other segment items include the following: acquisition costs, software expenses, corporate expenses, rent and maintenance expense, travel and event related expense, income tax (expense) benefit and other expenses (income).